389 related articles for article (PubMed ID: 9372881)
1. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
[TBL] [Abstract][Full Text] [Related]
2. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
3. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
4. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract][Full Text] [Related]
5. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
6. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
[TBL] [Abstract][Full Text] [Related]
7. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
[TBL] [Abstract][Full Text] [Related]
8. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
9. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
10. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
Pannek J; Partin AW
Semin Urol Oncol; 1998 Aug; 16(3):100-5. PubMed ID: 9741413
[TBL] [Abstract][Full Text] [Related]
11. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
12. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
Bangma CH; Wildhagen MF; Yurdakul G; Schröder FH; Blijenberg BG
BJU Int; 2004 Apr; 93(6):720-4. PubMed ID: 15049979
[TBL] [Abstract][Full Text] [Related]
13. Free and total human glandular kallikrein 2 in patients with prostate cancer.
Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
[TBL] [Abstract][Full Text] [Related]
14. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
[TBL] [Abstract][Full Text] [Related]
16. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
18. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
Sardana G; Diamandis EP
Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
[TBL] [Abstract][Full Text] [Related]
19. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
[TBL] [Abstract][Full Text] [Related]
20. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
Pannek J; Rittenhouse HG; Chan DW; Epstein JI; Walsh PC; Partin AW
J Urol; 1998 Apr; 159(4):1238-42. PubMed ID: 9507844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]